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Summary A 60-year-old woman who underwent operation due to severe aortic stenosis with
left ventricular dysfunction had frequent nonsustained ventricular tachycardia (NSVT) at night.
She had an increased apnea—hypopnea index and a reduction in minimum O2 saturation duringSleep disorder
breathing;
Heart failure;
Ventricular
tachycardia;
sleep, which was closely associated with the frequency of NSVT. Adaptive servo-ventilation (ASV)
therapy improved sleep disorder breathing (SDB) and also reduced ventricular arrhythmias.
These effects were associated with the attenuation of the sympathetic nerve activities by the
analysis of heart rate variability. ASV is expected to be effective in the treatment of ventricular
tachyarrhythmias in patients with heart failure and SDB.
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Introduction
Patients with heart failure (HF) often have sleep disor-
der breathing (SDB), especially Cheyne—Stokes respiration.
The prevalence of this association has been reported to be
between 40% and 50% in HF [1,2]. SDB has been shown to
be associated with an increased risk for the fatal arrhyth-
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ias and sudden cardiac death [3]. Approximately 20—35%
f patients with SDB have premature ventricular contrac-
ion and 3.0—5.3% of those have nonsustained ventricular
achycardia (NSVT) [4,5], suggesting that SDB may trigger
ethal ventricular arrhythmias. In patients with SDB, recur-
ent nocturnal apnea and hypopnea during sleep activate
ympathetic nerve activity, which may not only worsen HF
ut also trigger lethal ventricular arrhythmias. Adaptive
ervo-ventilation (ASV) is a novel therapy for SDB in patients
ith HF [6]. It can not only normalize the pattern of respi-
ation and quality of sleep, but also stabilize sympathetic
erve activity [7]. Therefore, it is also expected to reduce
ethal arrhythmias in patients with HF and SDB. This is a
Published by Elsevier Ltd. All rights reserved.
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which coincided with the decrease in SpO2.ASV (Auto Set
CS; Teijin Pharma, Tokyo) was started without oxygenation
and full face masks (Teijin Pharma) in the default settings;
expiratory positive airway pressure of 5 cm H2O, inspiratory
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21-Nov20-Nov19-Nov18-Nov17-Nov16-Nov15-Novigure 1 The electrocardiogram monitor shows sustained ve
he implantable cardioverter-deﬁbrillator.
rst report showing successful termination of ventricular
rrhythmias including NSVT by ASV in a patient with chronic
F.
ase report
60-year-old woman who had undergone aortic valve
eplacement for severe aortic stenosis with left ventricu-
ar (LV) dysfunction and prior history of pulmonary edema
as admitted to our cardiology ward for the treatment of
F. On admission, her heart rate was 60 beats per minute,
nd blood pressure was 94/68mmHg. She did not have jugu-
ar venous distension, lower leg edema, or rales. A 12-lead
lectrocardiogram (ECG) revealed complete atrioventric-
lar block with junctional escape rhythm and sporadic
pisodes of NSVT. Chest X-ray showed slight enlargement
f the heart, cardiothoracic ratio 56%, but no obvious pul-
onary congestion. Serum creatinine was 1.0mg/dl, and
lasma brain natriuretic peptide (BNP) value was elevated
o 659 pg/ml. Echocardiography showed diffuse LV hypoki-
esis with ejection fraction (EF) of 27%. No abnormalities in
rosthetic aortic valve were detected. The septal to pos-
erior wall motion delay was 264ms, and tissue Doppler
chocardiography demonstrated that the standard deviation
f time to peak systolic velocity of 12 segments of the LV
all at the basal and medial levels was 41.3ms, indicating
he presence of LV dyssynchrony. She had standard medi-
al treatment including carvedilol 10mg, enalapril 2.5mg,
urosemide 60mg, spironolactone 50mg, and amiodarone
00mg. Cardiac resynchronization therapy with deﬁbrilla-
or was performed for the treatment of HF with low EF and
omplete atioventricular block. Even after the stabilization
f HF, frequent NSVT persisted and electrical storm ter-
inated by implantable cardioverter-deﬁbrillator occurred
F
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tular tachycardia terminated by the anti-tachycardia pacing of
ainly during sleep (Figs. 1—3). A portable sleep monitoring
evice type 3 (Morpheus; Teijin Pharma, Tokyo, Japan) [8]
evealed that apnea—hypopnea index (AHI) was 15.2/h and
inimum oxygen saturation (SpO2) was decreased to 84% at
ight, conﬁrming the presence of SDB, mainly obstructive
leep apnea (Fig. 3). Moreover, 24-h ECG monitoring showed
hat ventricular arrhythmias such as premature ventricular
ontraction (PVC) and NSVT were noted during sleep (Fig. 2),igure 2 The number of nonsustained ventricular tachycar-
ia (NSVT) counted by bedside monitoring electrocardiogram.
t remarkably decreased after adaptive servo-ventilation (ASV)
herapy was initiated. The medications were not changed during
his period.
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Figure 3 The number of PVCs (A), NSVT (B), and autonomic nervous activity (C) before and during ASV therapy. NSVT was deﬁned as
three or more consecutive premature ventricular complexes that last no more than 30 s. LF/HF (dashed lines) indicates sympathetic
nerv
rdia;
tnerve activities and HF (solid lines) indicates parasympathetic
ventricular contraction; NSVT, nonsustained ventricular tachyca
frequency domain.
positive airway pressure (IPAP) of minimum 3 cm H2O, max-
imum 8—10 cm H2O. As expected, AHI decreased to 5.5/h
and minimum SpO2 increased to 91% after ASV (Fig. 4 and
Table 1). In parallel to this improvement in SDB, the number
of NSVT and sustained VT remarkably decreased from 25.3
Table 1 Statistical analysis in the change of each parame-
ter before and during ASV.
Before ASV During ASV p-value
AHI (/h) 15.2 ± 10.3 5.5 ± 3.3 0.0127
Minimum SpO2 (%) 88.1 ± 2.5 92.5 ± 1.1 0.0003
PVC (/h) 297.8 ± 188.7 67.3 ± 42.1 0.0042
NSVT (/h) 25.3 ± 21.1 1.4 ± 2.0 0.0060
LF/HF 0.37 ± 0.24 0.11 ± 0.03 0.0068
Values are presented as the means± SD. We used the paired t-
test for comparing continuous variables. For all tests, p < 0.05
was considered to be statistically signiﬁcant. ASV, adaptive
servo-ventilation; AHI, apnea hypopnea index; SpO2, oxy-
gen saturation; PVC, premature ventricular contraction; NSVT,
nonsustained ventricular tachycardia; LF/HF, low frequency
domain/high frequency domain.
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LF/HF, low frequency domain/high frequency domain; HF, high
o 1.4/h (Fig. 2 and Table 1). Moreover, PVC count and NSVT
ere dramatically decreased from 297.8 to 67.3/h (Fig. 3
nd Table 1). Furthermore, these beneﬁcial effects of ASV
n SDB and ventricular arrhythmias were associated with
he attenuation of activated sympathetic nervous activity at
ight as assessed by low frequency domain/high frequency
omain (LF/HF) by the analysis of heart rate variability
Fig. 3 and Table 1).
iscussion
his report demonstrated that ASV therapy was effective
or ventricular arrhythmias including NSVT in a HF patient
ith SDB. PVC and NSVT are commonly associated with SDB
4,5]. Moreover, the frequency of PVCs has been shown to
e positively correlated with severity of SDB in HF patients
1]. Previous studies reported that continuous positive air-
ays pressure (CPAP) therapy was effective in reducing
rrhythmias in patients with SDB. In obstructive sleep apnea
atients with HF, CPAP therapy improved LVEF, and reduced
he frequency of PVC during sleep by 58% [9]. Shimada
t al. [10] also reported CPAP could reduce the incidence
f NSVT in HF patients with SDB. In contrast, Craig et al.
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rigure 4 AHI (A) and minimum SpO2 (B) before and during ASV
xygen saturation.
11] could not demonstrate a decrease in arrhythmia fre-
uency in patients with SDB. ASV is one of the new therapies
or HF patients with SDB. Oldenburg et al. [6] reported
hat ASV could improve SDB, exercise capacity, LVEF, and
-terminal pro BNP in patients with HF and central sleep
pnea. However, the effects of ASV on ventricular arrhyth-
ias have never been demonstrated in previous reports.
herefore, the present ﬁndings that ASV therapy was effec-
ive for arrhythmias are the ﬁrst report, which may uncover
ts efﬁcacy in the treatment of HF. They are the extension
f the previous ﬁndings obtained by CPAP [10]. However,
e consider that ASV can be superior to CPAP for the sup-
ression of serious ventricular arrhythmias because ASV is
xpected to effectively inhibit sympathetic nervous system
ctivities compared with CPAP. There are several postulated
echanisms that sympathetic nervous system activated by
DB can result in fatal arrhythmias. At ﬁrst, hypoxia and
ypercapnia induced by SDB activate the sympathetic nerve
ystem via the chemoreceptors of the carotid artery, aor-
ic arch or respiratory control center, which cause frequent
VCs and fatal arrhythmias [12,13]. Secondly, the suppres-
ion of the extension of lungs by the apnea inhibits the
ctivity of the vagal nerve and inversely activates the sym-
athetic nerve [14]. Finally, sleep fragmentation due to the
pnea also causes sympathetic hyperactivity [15]. ASV can
upport the breathing of the pressure wave form similar to
pontaneous respiration and maintain 90% of the average
p
r
n
i, adaptive servo-ventilation; AHI, apnea hypopnea index; SpO2,
inute ventilation during most recent 3min by regulating
PAP and timing of the backup support automatically based
n the default mechanical setting, which may minimize the
ctivation of sympathetic activity [16]. In fact, the present
tudy demonstrated that the activated sympathetic nervous
ctivity was attenuated after ASV assessed by LH/HF (Fig. 2).
hese ﬁndings are also supported by the report by Gür et al.
7] that ASV could decrease serum levels of epinephrine and
orepinephrine.
ASV is one of the most effective devices for the
ppropriate regulation of sympathetic nerve in noninvasive
ntermittent positive pressure ventilation. It may be worth
sing ASV in order to control fatal arrhythmias in addition
o the administration of antiarrhythmic drugs. The present
eport suggests that ASV can improve the long-term progno-
is for patients with chronic HF by reducing cardiac events
ncluding sudden death or fatal arrhythmias, which, how-
ver, needs to be evaluated by a randomized controlled
rial.
There are several limitations in this report. First we
ould not compare the effects of ASV on arrhythmias with
ther noninvasive methods of ventilation. Second, accu-
ate polysomnography with electroencephalogram was not
erformed. Therefore we could not evaluate the exact cor-
elation between sleep, breathing, and the sympathetic
erve. Finally, we had no data of sympathetic nervous activ-
ty in day-time by using ambulatory electrocardiographic
by a
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[Successful termination of recurrent ventricular arrhythmias
monitoring in order to evaluate the relationship between
autonomic nervous activity and arrhythmia more precisely.
In conclusion, ASV could be effective for the termination
of recurrent NSVT in patients with HF and SDB.
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